The SARS-CoV-2 main protease as drug target

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

卷:30

Article

Ullrich, Sven¹  Nitsche, Christoph¹ 

[1] Australian Natl Univ, Res Sch Chem, Canberra, ACT 2601, Australia

关键词: COVID-19;    Coronavirus;    Protease inhibitors;    Peptidomimetics;    Antivirals;   

DOI  :  10.1016/j.bmcl.2020.127377

来源: Elsevier

【 摘 要 】

The unprecedented pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is threatening global health. The virus emerged in late 2019 and can cause a severe disease associated with significant mortality. Several vaccine development and drug discovery campaigns are underway. The SARS-CoV-2 main protease is considered a promising drug target, as it is dissimilar to human proteases. Sequence and structure of the main protease are closely related to those from other betacoronaviruses, facilitating drug discovery attempts based on previous lead compounds. Covalently binding peptidomimetics and small molecules are investigated. Various compounds show antiviral activity in infected human cells.

【 授权许可】

Free